Pharmaceuticals, Biotechnology and Life Sciences
MaxCyte has been engaged in a study with National Institutes of Health’s (NIH) allergy and infection section to show certain CYBB gene behaviour in patients with X-linked chronic granulomatous disease (X-CGD).
Ablynx has dosed the first patient in the Phase IIb “RESPIRE” dose-ranging efficacy study of ALX-0171, its novel inhaled drug…
The Food and Drug Administration is warning consumers not to purchase or use PNC-27, a product promoted and sold through http://PNC27.com,…
Celyad has activated a second clinical site in Belgium for the , with the registration of a pancreatic cancer patient…
Eli Lilly and Merck have expand an existing immuno-oncology collaboration through a subsidiary to add a new study of Lilly’s…
Evgen Pharma’s anti-stress drug SFX-01, which is currently in its Phase II study has shown good results and it can proceed as planned.
A clinical stage biotechnology company, ValiRX, said on Wednesday that its VAL201 personalised Phase l/II prostate cancer study brought positive results.
NeuroVive Pharmaceutical AB, the mitochondrial medicine company, has signed collaboration agreement with Karolinska Institutet, Stockholm, Sweden, regarding development of the company’s…
European Commission has granted marketing authorisation for Novo Nordisk’s Fiasp for the treatment of diabetes in adults.
The European Patent Office has decided to grant Active Biotech’s patent application covering tasquinimod for use in the treatment of…